uploads///Graph

Illumina: Focusing on the $20 Billion Genome Sequencing Market

By

Sep. 29 2015, Updated 7:12 p.m. ET

The genome sequencing market

Illumina (ILMN) is a unique biotechnology company with a focus on the $20 billion genome sequencing market.

The above diagram shows the commercial potential of the major branches across the genome sequencing market. The shaded portions in the diagram indicate the current estimated market penetration percentages.

Article continues below advertisement

Oncology

Genome changes are responsible for transforming a normal cell into a cancerous cell. Illumina works in collaboration with pharmaceutical and biotechnology companies to identify these changes and develop targeted therapies for patients. With major biotechnology companies such as Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) increasing their focus on the $100 billion oncology market, the demand for Illumina’s services is expected to rise significantly.

Life sciences

Illumina’s core business is life sciences. Laboratory researchers in medical research centers, universities, government institutions, and pharmaceutical companies are Illumina’s main users. The company’s products are also used in agrigenomics to identify desirable traits in plants and livestock. Genetic research can lead to better agricultural output.

Article continues below advertisement

Reproductive and genetic health

Illumina products are also used in reproductive healthcare to avoid miscarriages and failures in other pregnancy-related therapies. These products can also help to identify genetic abnormalities in the fetus.

New and emerging

In addition to these well-established markets, Illumina’s exploring other opportunities such as transplant diagnostics to evaluate donor and patient compatibility, forensic genomics to investigate criminal cases, and consumer genomics to reveal family trees.

You can get exposure to Illumina’s strong genome sequencing portfolio yet reduce company-specific risks by investing in the iShares Nasdaq Biotechnology ETF (IBB). Illumina accounts for 4.09% of its total holdings.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.